Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase IV trial is evaluating whether morning versus afternoon administration of standard of care immunotherapy impacts its effectiveness in treating patients with solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Immunotherapy with monoclonal antibodies may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Circadian rhythm refers to the internal biological clock in which various processes in the body, including immune cell activity, are controlled by the time of day. Exactly how this works is not fully understood, and the researchers want to see if circadian rhythm control of the immune system can influence response to immunotherapy based on whether it is given in the morning (before 10:30 am) or afternoon (12:30pm). The time of day that immunotherapy is given (morning versus afternoon) may impact the effectiveness in treating patients with advanced or metastatic solid tumors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony zaawansowany lub przerzutowy nowotwór litego pochodzenia (m.in. rak płuca, gardła, nerki, wątroby, żołądka)
- •Kwalifikacja do leczenia zatwierdzonym przez FDA lekiem immunoterapii
- •Mierzalne ogniska choroby widoczne w badaniach obrazowych
- •Podpisana świadoma zgoda na udział w badaniu
✗ Disqualifies
- •Wcześniejsze leczenie immunoterapią
- •Stosowanie leków hamujących system immunologiczny w ciągu ostatnich 28 dni
- •Niekontrolowana autoimmunologiczna choroba wymagająca immunosupresji
- •Przerzuty do mózgu, które są aktywne i niekontrolowane
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
OHSU Knight Cancer Institute
Portland, United States
Trial contact
Rajat Thawani
Rajat Thawani
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.